PALM BEACH, Florida, September 26, 2018 /PRNewswire/ --
Financialnewsmedia.com News Commentary
Biotech and Big Pharma companies are facing new realities, prospects and success measures in today's dynamic cardiovascular disease market. According to the study conducted by Global Burden of Diseases estimate that the death rate due to CVD is 235 per 100,000 in global population. According to WHO, cardiovascular diseases account for 31% deaths globally which is approximately 17.7 million individuals. Out of these 80% of the CVD deaths are due to stroke and heart attacks. New drugs that target such conditions as angina, arrhythmia, coronary artery disease, hypertension, myocardial infarction or other disorders that have a large impact on cardiovascular health are also proving to have large financial gains for companies developing these products. Active biotech and pharma companies in the markets this week include Nutriband Inc. (OTC:NTRB), Amarin Corporation (NASDAQ:AMRN), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Jaguar Health Inc. (NASDAQ:JAGX), Geron Corporation (NASDAQ:GERN).
Nutriband Inc. (OTCQB: NTRB) BREAKING NEWS : Nutriband is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc. The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares.
According to the agreement, Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel's pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase plus rights to Carmel's clinically tested nutraceutical line. This includes MET-191, a nutritional supplement which has demonstrated benefit of lipid management, appetite control, and weight management, while improving factors that contribute to the metabolic syndrome. Carmel Biosciences is a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. The Carmel Biosciences team combines a deep understanding of lipid biochemistry and clinical expertise in the cardiovascular and metabolic space.
In December 2017 Carmel Biosciences received FDA approval on its first drug PREXXARTAN, the first and Only approved oral liquid dosage form of the angiotensin receptor blocker (ARB) valsartan in the United States. Oral liquid dosage medications boast a number of benefits such as being better for patients with discomfort swallowing pills, they can often boast faster absorption and flexibility of dosage.
PREXXARTAN™ (valsartan oral solution) is indicated for treatment of hypertension in adults and children six years and older. PREXXARTAN™ is also indicated for use as therapy for the treatment of heart failure (NYHA class II-IV). Additionally, PREXXARTAN™ has also been indicated for stable left ventricular failure or left ventricular dysfunction after myocardial infarction. Read this and more news for NTRB at http://www.financialnewsmedia.com/news-ntrb
Other recent developments or market movers in the medical industry include:
Amarin Corporation (NASDAQ:AMRN) News. HLS Therapeutics Inc. (TSXV:HLS.V) recently announced that Amarin Corporation plc recently issued topline results from the Vascepa® cardiovascular ("CV") outcomes trial, REDUCE-IT™, a global study of 8,179 statin-treated adults with elevated CV risk. REDUCE-IT met its primary endpoint demonstrating an approximately 25% relative risk reduction, to a high degree of statistical significance (p<0.001), in major adverse CV events ("MACE") in the intent-to-treat patient population with use of Vascepa 4 grams/day as compared to placebo. HLS has in-licensed the rights to Vascepa for the Canadian market. Patients enrolled in REDUCE-IT had LDL-C between 41-100 mg/dL (median baseline LDL-C 75 mg/dL) controlled by statin therapy and various CV risk factors including persistent elevated triglycerides ("TGs") between 150-499 mg/dL (median baseline 216 mg/dL) and either established CV disease (secondary prevention cohort) or diabetes mellitus and at least one other CV risk factor (primary prevention cohort).
Applied Genetic Technologies Corporation (NASDAQ:AGTC) this week the company announced it has appointed William Aliski to the company's Board of Directors. "Bill will be an invaluable addition to the AGTC Board of Directors and leadership team," said Sue Washer, President and CEO of AGTC. "His deep knowledge of biotechnology and the rare disease space, coupled with his consistent record of providing strategic counsel to clinical-stage companies, will be beneficial to AGTC as we continue to advance our lead candidates through clinical trials." Mr. Aliski has extensive leadership and management experience in the life sciences industry, and has contributed to the commercialization of a number of rare disease products. His professional experience includes roles as Chief Commercial Officer for FoldRx, an orphan drug development and discovery company later acquired by Pfizer, General Manager for BioMarin Europe, and executive-level positions at Transkaryotic Therapies, Inc. and Genzyme Corp. He also has served as a commercial consultant for numerous biotechnology companies. He currently serves on the board of Ultragenyx Pharmaceutical, and was formerly a board member of Edimer Pharmaceuticals and Scioderm Pharmaceuticals. He earned an undergraduate degree in economics and a Master of Social Planning from Boston College as well as an MPA from the Kennedy School of Government at Harvard University.
Jaguar Health Inc. (NASDAQ:JAGX) earlier this week announced it has entered into a strategic partnership with Knight Therapeutics Inc. (TSX:GUD.TO), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. It is a Distribution, License and Supply Agreement (the Agreement) that grants Knight the exclusive right to commercialize Mytesi® (crofelemer 125 mg delayed-release tablets) and related products in Canada and Israel and a right of first negotiation to commercialize Mytesi and related products in specified Latin American countries. Mytesi is an FDA-approved product in the U.S. indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Jaguar is also pursuing possible follow-on indications for Mytesi in cancer therapy-related diarrhea (CTD), an important supportive care indication for patients undergoing cancer treatment; for rare disease indications for infants and children with congenital diarrheal disorders and short bowel syndrome (SBS); for irritable bowel syndrome (IBS); for supportive care for inflammatory bowel disease (IBD); and as a second-generation anti-secretory agent for use in cholera patients.
Geron Corporation (NASDAQ:GERN) came to a close on Tuesday at $6.38 up 2.90% with over 11 million shares traded by the market close. Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Nutriband Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.